EMR 62218

Drug Profile

EMR 62218

Latest Information Update: 26 Jul 2006

Price : $50

At a glance

  • Originator Merck KGaA
  • Class Antipsychotics; Sleep disorder therapies
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia; Sleep disorders

Most Recent Events

  • 26 Jul 2006 No development reported - Phase-I for Schizophrenia (unspecified route)
  • 26 Jul 2006 No development reported - Phase-I for Sleep disorders (unspecified route)
  • 02 Apr 2004 Phase-I clinical trials in Sleep disorders (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top